glucagon like peptide 1 glp 1 agonists Glucagon-like 1(GLP-1) receptor in the management of the patient with type 2diabetes mellitus and chronic kidney disease: an approach for the nephrologist Cardiovascular effects of Glucagon-like peptide
Description
Our findings strongly suggest the answer is yes. Primes recent real-world study found 63% of high-potency GLP-1 (Wegovy or Zepbound) users who started treatment in Q1 2024 are still taking their medication after a year
The GLP-1 gold rush is getting a lot less photogenic
oral regimens), and trial endpoints better tuned to metabolic mechanisms
The messaging is about affordability and access
The CEO of the Alliance for Pharmacy Compounding unpacks how the ruling affects telehealth providers and what it could signal for future GLP-1 entrants and market dynamics:
In this narrative review we introduce the preclinical data related to this receptor pathway and pancreatic ductal adenocarcinoma
